Everbright's Research Reports suggest that liver fibrosis is liver damage caused by inflammation or metabolic disorders, which can be induced by various factors such as alcohol, viruses, and fatty liver. If not intervened and treated promptly, it may lead to cirrhosis or liver cancer. However, there is currently a lack of chemical or biological drugs for the treatment of liver fibrosis. According to China's "Guidelines for the Diagnosis and Treatment of Liver Fibrosis with Traditional Chinese and Western Medicine" (2019 edition), Chinese Patent Medicine is primarily used in clinical settings, with treatments mainly aimed at addressing the underlying causes. In March 2024, the first Innovative Drug for the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH), Rezdiffra (Resmetirom), was officially approved by the FDA for sale, marking a breakthrough in Innovative Drugs for liver fibrosis treatment. As of November 2024, several liver fibrosis treatment drugs have made progress globally. From biotech companies such as Gilead Sciences and Viking Therapeutics to large pharmaceutical companies like BI and Novo-Nordisk A/S, positive data on MASH treatment drugs have been announced. Additionally, the drug F351 (hydroxyketone), designed for treating fibrosis caused by hepatitis B, has also completed the enrollment of patients in clinical phase 3, becoming the fastest progressing research product for hepatitis B-related fibrosis.